Clarivate Report Ranks China as World’s Second-Largest Market for New Drug Launches
I'm PortAI, I can summarize articles.
Clarivate's report highlights Mainland China's rise as the world's second-largest market for new drug launches, with an 18% global share in 2024. The biopharmaceutical sector is transitioning from rapid growth to quality-driven development, gaining global recognition. Between 2019-2023, 66% of new active substances approved globally were also approved in China. Chinese biopharma out-licensing deals reached $50 billion, indicating its growing global influence. The analysis is based on Clarivate's databases and a framework developed with Healthcare Executive.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments